Ademethionine
ApprovedSmall molecule
Ademethionine is one of 13 small molecule programs targeting Cholestasis. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Cholestasis
#DrugCompanyPhaseTrials
1Intralipid
AstraZenecaApproved
Smoflipid
FFresenius
Approved
Actigall
AbbViePhase 2
Polyene Phosphatidyl Choline
ZZhejiang Hisun Pharmaceutical Co. Ltd.
Approved
Lynavoy
IIntercept Pharmaceuticals
Phase 3
Ademethionine
ZZhejiang Hisun Pharmaceutical Co. Ltd.
Approved
Omegaven
UUniversity of California, San Diego
Phase 2
IC-Green
CCHX Technologies Inc.
Phase 1
A4250
AAlbireo, an Ipsen Company
Phase 2
Ursodeoxycholic Acid
Daewoong Pharmaceutical Co. LTD.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ademethionine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details